TABLE 3.

Results of CMA for APOE4’s effect on survival up to age 85+ mediated by AgeMaxW and SlopeW. Results evaluated at different strata. [TE (LC, UC), pval]: [total effect estimate (lower 95% confidence interval and upper 95% confidence interval), p-value of total effect estimate], similarly for NIE (natural indirect effect), PM (percentage mediated), CDE (controlled direct effect), and NDE (natural direct effect). TE compares the chances of survival for APOE4 carriers vs. non-carriers while taking into account the effect of the mediator. NIE holds the treatment constant and considers the effect of the mediator only. PM gives the percentage of the total effect that is mediated by the mediator. NDE and CDE compare the chances of survival for the two “treatment” groups (carriers vs. non-carriers) without considering the effect of the mediator.

Mediator	Treatment	Strata	[TE (LC, UC), pval]	[NIE (LC, UC), pval]	[PM (LC, UC), pval]	[CDE (LC, UC), pval]	[NDE (LC, UC), pval]	N
AgeMaxW	APOE4	Total	[1.213 (1.034, 1.391), 0.020]*	[1.026 (1.003, 1.049), 0.028]*	[14.244 (−1.382, 29.870), 0.074]	[1.468 (1.034, 1.391), 0.020]*	[1.183 (1.007, 1.358), 0.042]*	3,287
AgeMaxW	APOE4	Male	[1.207 (1.029, 1.384), 0.023]*	[1.025 (1.003, 1.048), 0.027]*	[14.365 (−1.374, 30.104), 0.074]	[1.468 (1.034, 1.391), 0.020]*	[1.177 (1.003, 1.351), 0.046]*	3,287
AgeMaxW	APOE4	Female	[1.211 (1.032, 1.390), 0.021]*	[1.025 (1.003, 1.048), 0.027]*	[14.283 (−1.380, 29.946), 0.074]	[1.468 (1.034, 1.391), 0.020]*	[1.181 (1.006, 1.356), 0.043]*	3,287
AgeMaxW	APOE4	White	[1.211 (1.032, 1.390), 0.021]*	[1.026 (1.003, 1.048), 0.028]*	[14.283 (−1.380, 29.946), 0.074]	[1.468 (1.034, 1.391), 0.020]*	[1.181 (1.006, 1.356), 0.043]*	3,287
AgeMaxW	APOE4	Black	[1.185 (1.010, 1.361), 0.039]*	[1.023 (1.003, 1.044), 0.026]*	[14.619 (−1.474, 30.713), 0.075]	[1.468 (1.034, 1.391), 0.020]*	[1.158 (0.988, 1.329), 0.069]	3,287
SlopeW	APOE4	Total	[1.222 (1.034, 1.410), 0.021]*	[1.036 (1.007, 1.065), 0.015]*	[19.102 (−0.502, 38.705), 0.056]	[1.256 (0.934, 1.578), 0.119]	[1.180 (0.995, 1.363), 0.055]	3,020
SlopeW	APOE4	Male	[1.221 (1.033, 1.409), 0.021]*	[1.036 (1.007, 1.065), 0.015]*	[19.122 (−0.437, 38.682), 0.055]	[1.256 (0.934, 1.578), 0.119]	[1.179 (0.996, 1.362), 0.056]	3,020
SlopeW	APOE4	Female	[1.221 (1.033, 1.408), 0.021]*	[1.036 (1.007, 1.064), 0.014]*	[19.135 (−0.389, 38.659), 0.055]	[1.256 (0.934, 1.577), 0.119]	[1.178 (0.995, 1.361), 0.056]	3,020
SlopeW	APOE4	White	[1.221 (1.033, 1.408), 0.021]*	[1.036 (1.007, 1.064), 0.014]*	[19.135 (−0.389, 38.659), 0.055]	[1.256 (0.934, 1.577), 0.119]	[1.178 (0.995, 1.361), 0.056]	3,020
SlopeW	APOE4	Black	[1.221 (1.033, 1.408), 0.021]*	[1.036 (1.007, 1.065), 0.014]*	[19.131 (−0.401, 38.663), 0.055]	[1.256 (0.934, 1.577), 0.119]	[1.178 (0.995, 1.362), 0.056]	3,020

Effect estimates are presented on the relative risk scale. *, significant p-value (<0.05); N, number of observations used.